Form 4: Teva Director Sells 200,000 Shares in Pre-Planned Trade

Teva Pharmaceutical Industries Director Roberto Mignone reported the sale of 200,000 ordinary shares for approximately $4.82 million.

Summary

• Roberto Mignone, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), sold 200,000 ordinary shares.
• The transaction occurred on November 6, 2025, at a weighted average price of $24.1094 per share, totaling approximately $4,821,880.
• The shares were sold in multiple transactions with prices ranging from $24.0050 to $24.2450.
• This sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the transaction, Mr. Mignone directly beneficially owns 105,315 ordinary shares.
• Additionally, Mr. Mignone indirectly beneficially owns 495,000 ordinary shares held by Swiftcurrent Master Fund Ltd., where he is the manager of the investment adviser, Bridger Management, LLC. He disclaims beneficial ownership except to the extent of his indirect pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the disclosure that the transaction was made pursuant to a Rule 10b5-1(c) plan indicates a pre-scheduled sale, which typically mitigates concerns about opportunistic trading based on non-public information. It's a routine disclosure for a director's personal trading activity.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale and mitigating concerns about opportunistic insider trading.

Negatives

• A director selling a significant number of shares could be perceived negatively by some investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this.

Future Outlook

This Form 4 filing is a transactional report and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape within the pharmaceutical sector. It reflects an individual director's trading activity rather than a company-wide strategic move.

Corporate Governance

Stakeholder Impact

• Shareholders may observe the director's sale and interpret it in various ways, though the 10b5-1 plan typically reduces negative speculation.
• Regulatory bodies (SEC) are informed of the change in beneficial ownership, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Recommendation

The filing reports a director's sale of shares, which, while a notable insider transaction, was conducted under a pre-arranged Rule 10b5-1(c) plan. This suggests the sale was not based on new, material non-public information. Without additional context on company fundamentals, strategic shifts, or a pattern of widespread insider selling, this single transaction does not warrant a change from a 'hold' recommendation. Investors should monitor broader company performance and market conditions.

Keywords

Teva Pharmaceutical Industries, TEVA, Roberto Mignone, Insider Sale, Form 4, Director Transaction, Share Sale, Pharmaceuticals, 10b5-1 Plan